; (E) the establishment of effective TB infection control in all relevant congregant settings, including hospitals, clinics, and prisons; (F) a description of progress in implementing measures to reduce TB incidence, including actions— (i) to expand active case finding and contact tracing to reach vulnerable groups; and (ii) to expand TB preventive therapy, engagement of the private sector, and diagnostic capacity; (G) a description of progress to expand diagnosis, prevention, and treatment for all forms of TB, including in pregnant women, children, and individuals and groups at greater risk of TB, including migrants, prisoners, miners, people exposed to silica, and people living with HIV/AIDS, disaggregated by sex; (H) the rate of successful completion of TB treatment for adults and children, disaggregated by sex, and the number of individuals receiving support for treatment completion; (I) the number of people, disaggregated by sex, receiving treatment for MDR–TB, the proportion of those treated with the latest regimens endorsed by the World Health Organization, factors impeding scale up of such treatment, and a description of progress to expand community-based MDR–TB care; (J) a description of TB commodity procurement challenges, including shortages, stockouts, or failed tenders for TB drugs or other commodities; (K) the proportion of health facilities with specimen referral linkages to quality diagnostic networks, including established testing sites and reference labs, to ensure maximum access and referral for second line drug resistance testing, and a description of the turnaround time for test results; (L) the number of people trained by the United States Government to deliver high-quality TB diagnostic, preventative, monitoring, treatment, and care services; (M) a description of how supported activities are coordinated with— (i) country national TB plans and strategies